You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Danish informatics firm is exploring analytical tools for its InWeb_InBioMap network, which currently contains more than 700,000 protein-protein interactions.
The funding will be used to support the the newly established ME/CFS Collaborative Research Center at Stanford University.
The creator of the Genome Aggregation Database sees an ever-expanding GnomAD database as a centerpiece to improving the diagnosis of rare diseases.
Using RNA sequences for thousands of cells, researchers looked at head and neck squamous cell carcinomas and proposed streamlined expression subtypes.
Researchers are now using the approach to allow genome-wide sequencing to monitor disease and to investigate treatment response and resistance without the need for tissue biopsy.
Business Insider reports that researchers are making headway in linking genetic variants to mental illness risk.
Alterations affecting the antigen presentation-related gene B2M appeared to be over-represented in melanomas with checkpoint blockade non-response or resistance.
The initiative's four research projects will use use genetic and other technologies to detect and treat cancer at its earliest stages.
A new set of papers reveals a range of gene expression influencers, identified using thousands of samples collected for the Genotype-Tissue Expression project.
Verge is working with four academic institutions to create a broad resource for the translation of preclinical models of amyotrophic lateral sclerosis research.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.